

## **IGRA Product Profile**



## RIDA®QUICK TB

Manufacturer:	R-Biopharm AG, Darmstadt, Germany
Type of IGRA:	Lateral flow immunoassay utilizing IP-10 detection and proprietary instrument
Approval status:	EU IVDR (Class C) Note: Authorization for use by one of the Regulatory Authorities of the Founding Members of the Global Harmonization Task Force, i.e., the regulatory authorities of the USA, the European Union, Japan, Canada and Australia, when stringently assessed (as Class C or D), meets the eligibility criteria for procurement using Global Fund resources
Global access pricing:	Cost of reagents per patient tested: \$13.89 Cost of instrument (RIDA®Q3 reader): \$1,700 Available through PFSCM (prices as of August 2025 and subject to change)
Type of laboratory required:	Decentralized laboratory
Required equipment:	<ul> <li>37°C ± 1°C incubator</li> <li>Centrifuge for harvesting plasma</li> <li>Basic pipetting equipment</li> <li>RIDA®Q3 reader for readout and result interpretation</li> </ul>
Blood collection tubes:	Proprietary: Negative control, TB-specific (ESAT-6 and CFP-10 antigens), Positive control
Stimulating antigens:	ESAT-6, CFP-10 The biomarker detected is interferon-gamma induced protein 10 (IP-10), which is secreted in concentrations up to 100 times higher than interferon-gamma
Total processing time:	Antigen stimulation: 16-24 hours Lateral flow test: 15 minutes for results
Manufacturer website and contact information:	https://clinical.r-biopharm.com/diagnostics/tuberculosis/ tb-diagnostics@r-biopharm.de

Version: 14 August 2025



## **IGRA Product Profile**

## **Product images:**



RIDA®QUICK TB cartridge with RIDA®Q3 reader



RIDA® TB Tubes

Version: 14 August 2025